423 related articles for article (PubMed ID: 33389461)
1. The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease: a meta-analysis and systematic review.
Qie S; Jiao N; Duan K; Li J; Liu Y; Liu G
Int Urol Nephrol; 2021 May; 53(5):985-997. PubMed ID: 33389461
[TBL] [Abstract][Full Text] [Related]
2. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
[TBL] [Abstract][Full Text] [Related]
3. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study.
Fishbane S; El-Shahawy MA; Pecoits-Filho R; Van BP; Houser MT; Frison L; Little DJ; Guzman NJ; Pergola PE
J Am Soc Nephrol; 2021 Mar; 32(3):737-755. PubMed ID: 33568383
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A systematic review and meta-analysis.
Zheng L; Tian J; Liu D; Zhao Y; Fang X; Zhang Y; Liu Y
Br J Clin Pharmacol; 2022 Mar; 88(3):919-932. PubMed ID: 34428860
[TBL] [Abstract][Full Text] [Related]
5. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.
Provenzano R; Besarab A; Sun CH; Diamond SA; Durham JH; Cangiano JL; Aiello JR; Novak JE; Lee T; Leong R; Roberts BK; Saikali KG; Hemmerich S; Szczech LA; Yu KP; Neff TB
Clin J Am Soc Nephrol; 2016 Jun; 11(6):982-991. PubMed ID: 27094610
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis.
Zheng Q; Yang H; Fu X; Huang Y; Wei R; Wang Y; Liu YN; Liu WJ
Nephrol Dial Transplant; 2021 Aug; 36(9):1603-1615. PubMed ID: 33051677
[TBL] [Abstract][Full Text] [Related]
7. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.
Chen N; Hao C; Peng X; Lin H; Yin A; Hao L; Tao Y; Liang X; Liu Z; Xing C; Chen J; Luo L; Zuo L; Liao Y; Liu BC; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
N Engl J Med; 2019 Sep; 381(11):1001-1010. PubMed ID: 31340089
[TBL] [Abstract][Full Text] [Related]
8. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.
Chen N; Hao C; Liu BC; Lin H; Wang C; Xing C; Liang X; Jiang G; Liu Z; Li X; Zuo L; Luo L; Wang J; Zhao MH; Liu Z; Cai GY; Hao L; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
N Engl J Med; 2019 Sep; 381(11):1011-1022. PubMed ID: 31340116
[TBL] [Abstract][Full Text] [Related]
9. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
Akizawa T; Iwasaki M; Yamaguchi Y; Majikawa Y; Reusch M
J Am Soc Nephrol; 2020 Jul; 31(7):1628-1639. PubMed ID: 32493693
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials.
Provenzano R; Szczech L; Leong R; Saikali KG; Zhong M; Lee TT; Little DJ; Houser MT; Frison L; Houghton J; Neff TB
Clin J Am Soc Nephrol; 2021 Aug; 16(8):1190-1200. PubMed ID: 34362786
[TBL] [Abstract][Full Text] [Related]
11. Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis.
Liu J; Zhang A; Hayden JC; Bhagavathula AS; Alshehhi F; Rinaldi G; Kontogiannis V; Rahmani J
Pharmacol Res; 2020 May; 155():104747. PubMed ID: 32171893
[TBL] [Abstract][Full Text] [Related]
12. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
Besarab A; Provenzano R; Hertel J; Zabaneh R; Klaus SJ; Lee T; Leong R; Hemmerich S; Yu KH; Neff TB
Nephrol Dial Transplant; 2015 Oct; 30(10):1665-73. PubMed ID: 26238121
[TBL] [Abstract][Full Text] [Related]
13. Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
Akizawa T; Iwasaki M; Otsuka T; Reusch M; Misumi T
Adv Ther; 2019 Jun; 36(6):1438-1454. PubMed ID: 30953333
[TBL] [Abstract][Full Text] [Related]
14. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
Provenzano R; Besarab A; Wright S; Dua S; Zeig S; Nguyen P; Poole L; Saikali KG; Saha G; Hemmerich S; Szczech L; Yu KH; Neff TB
Am J Kidney Dis; 2016 Jun; 67(6):912-24. PubMed ID: 26846333
[TBL] [Abstract][Full Text] [Related]
15. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
Akizawa T; Otsuka T; Reusch M; Ueno M
Ther Apher Dial; 2020 Apr; 24(2):115-125. PubMed ID: 31222951
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of roxadustat for the treatment of anemia in non-dialysis dependent chronic kidney disease patients: An updated systematic review and meta-analysis of randomized clinical trials.
Abdelazeem B; Shehata J; Abbas KS; El-Shahat NA; Malik B; Savarapu P; Eltobgy M; Kunadi A
PLoS One; 2022; 17(4):e0266243. PubMed ID: 35363823
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat on renal anemia in non-dialysis-dependent chronic kidney disease: a systematic review and meta-analysis.
Jia L; Dong X; Yang J; Jia R; Zhang H
Ann Transl Med; 2019 Dec; 7(23):720. PubMed ID: 32042736
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.
Chen N; Qian J; Chen J; Yu X; Mei C; Hao C; Jiang G; Lin H; Zhang X; Zuo L; He Q; Fu P; Li X; Ni D; Hemmerich S; Liu C; Szczech L; Besarab A; Neff TB; Peony Yu KH; Valone FH
Nephrol Dial Transplant; 2017 Aug; 32(8):1373-1386. PubMed ID: 28371815
[TBL] [Abstract][Full Text] [Related]
19. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS).
Shutov E; Sułowicz W; Esposito C; Tataradze A; Andric B; Reusch M; Valluri U; Dimkovic N
Nephrol Dial Transplant; 2021 Aug; 36(9):1629-1639. PubMed ID: 33630072
[TBL] [Abstract][Full Text] [Related]
20. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
